The COVID-19 pandemic has been extremely hard on all of us. Closed up inside our homes, isolated from friends and family, and with many unemployed, especially within the services industry, we are all reaching a mental breaking point.
Mental health issues such as anxiety, suicidal thoughts, depression, substance abuse, and psychosocial dysfunction have soared among the general population as the pandemic continues unabated. More than 800,000 people kill themselves every year – that’s more than the population of Washington DC.
First responders and medical staff have been the groups hardest hit this past year. They have been on the front lines fighting COVID and have seen the death and devastation the virus wreaks firsthand. Along with military personnel, these groups are now facing sharp increases in post-traumatic stress disorder (PTSD) symptoms.
Simply put, society is facing a global mental health crisis at a scale we’ve never seen before mostly fueled by fear and isolation.
Urgent Call for Alternative Mental Health Therapies
Traditional pharmaceutical-based mental health therapies have their downside; the side effects are often worse than the original mental health issues a patient is trying to overcome.
A new approach to mental health therapy is desperately needed, and scientists are now looking at plant-based compounds that are showing promising positive clinical results.
Psilocybin, found in a unique species of mushrooms, is the latest plant-based organic compound that researchers are exploring to be powerfully effective in therapies for treating PTSD, opioid addictions, alcoholism and chronic depression/anxiety disorders.
“(Psilocybin) potentially provides a completely new model in psychiatry of a medication that works rapidly as both an antidepressant and anxiolytic and has sustained benefit for months,” Stephen Ross, MD., Psychiatrist at New York University Langone, said.
Recent clinical studies have shown that psilocybin in conjunction with psychological therapy has been highly effective to treat a wide range of psychiatric conditions, including end-of-life anxiety and depression, alcohol and tobacco addictions, obsessive compulsive disorder, and treatment-resistant major depression3.
The Food and Drug Administration (FDA) has given its blessing to the new studies by giving the hallucinogenic compound psilocybin a “Breakthrough Therapy” designation. This designation is designed to expedite the development and review of drugs and puts psilocybin on a fast track for approval and offers intensive guidance from the FDA.
In addition to psilocybin, compounds found within the cannabis plant, cannabinoids, especially CBD, have already been shown to help patients with severe anxiety, and ongoing studies are showing promise in treating PTSD and depression.
Pioneering Mental Health Treatments Using Psychedelic and CBD Compounds
A literal paradigm shift in mental health therapy is underway. Psychedelics and cannabinoids have opened up new areas of research to find positive therapies based on organic compounds from these plants.
Today, there are only a handful of companies that possess the expertise in medical discovery and research to deliver psilocybin and cannabis formulations for health and wellness applications.
One such company, is my company, Allied Corp. (OTCQB: ALID), has been leading the charge in developing proprietary cannabidiol (CBD) and psilocybin compounds to treat PTSD, anxiety, depression and other mental health issues, and are showing promising results. The company now holds two provisional patents for its CBD formula as well as one provisional patent for psilocybin.
Allied Corp. is currently conducting Phase I clinical trials with a proprietary compound of psilocybin and CBD called ALID-10 and ALID-11. These compounds are being tested for their efficacy in treating PTSD and other mental disorders. If approved, this could be a turning point in the quest to help millions of people worldwide. Just to put things in perspective as to how important it is to find new and effective ways to treat mental illness, every day approximately 22 active-duty troops, guardsmen, veterans, or reservists die by suicide.
If approved, this could be a turning point in the quest to help millions of people worldwide. Just to put things in perspective as to how important it is to find new and effective ways to treat mental illness, every day approximately 22 active-duty troops, guardsmen, veteran, or reservist die by suicide.the author writes
Adam Smith, a former US Green Beret who suffered from PTSD, has become a spokesperson and is now working with Allied Corp. His account of how he escaped suicide is as chilling as they come.
“I went from sitting on a couch in the middle of a small town in Kentucky, beyond drunk, suicide note on the table and a pistol in my mouth, PRAYING for a miracle,” Smith says CBD helped turn his life around, and he is now a firm believer in its power.
His focus is sharing the power of these plant-based compounds with others who are suffering from PTSD and searching for something to ease their pain and enable them to live a healthy life again.
Similar to how cannabis has helped successfully treat cancer patients and reduce seizures for people with epilepsy, I think the same thing will happen with psychedelics.
Whole new frontiers will open up to doctors to save lives and offer safe and effective therapeutic access to substances that have the ability to induce a feeling of connection for people who are seemingly suffering alone and gives them hope and the actual ability to get well and enjoy a better tomorrow.